Quick Answer
Sigyn Therapeutics, Inc. reported Net Income of -$3.34 million for fiscal year 2024.
Sigyn Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2024 | -$3.34M | +19.4% |
| 2023 | -$4.15M | -41.5% |
| 2022 | -$2.93M | +2.5% |
| 2021 | -$3.00M | -138.5% |
| 2020 | -$1.26M | +59.0% |
| 2019 | -$3.07M | -17.3% |
| 2018 | -$2.62M | +38.4% |
| 2017 | -$4.25M | -57.8% |
| 2015 | -$2.69M | -595.2% |
| 2014 | -$387.5K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$578.5K | +51.7% | +60.1% |
| June 30, 2025 | -$1.45M | -68.3% | -117.1% |
| March 31, 2025 | -$668.6K | +11.8% | +44.1% |
| September 30, 2024 | -$1.20M | -32.2% | -38.8% |
| June 30, 2024 | -$862.4K | -19.3% | -13.8% |
| March 31, 2024 | -$758.1K | +43.5% | +16.3% |
| September 30, 2023 | -$905.7K | -24.7% | -25.3% |
| June 30, 2023 | -$723.1K | -8.5% | +46.1% |
- Sigyn Therapeutics, Inc. showed an increase of +19.4% in Net Income compared to the prior fiscal year.
- Over the 2014–2024 period, Sigyn Therapeutics, Inc.’s net income has declined by 761.9% (from -$387.5 thousand to -$3.34 million).
- The most recent figure is from Sigyn Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: